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Abstract
The immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients initiating
antiretroviral therapy (ART) results from restored immunity to specific infectious or non-infectious
antigens. A paradoxical clinical worsening of a known condition or the appearance of a new
condition after initiating therapy characterizes the syndrome. Potential mechanisms for the
syndrome include a partial recovery of the immune system or exuberant host immunological
responses to antigenic stimuli. The overall incidence of IRIS is unknown, but is dependent on the
population studied and its underlying opportunistic infectious burden. The infectious pathogens
most frequently implicated in the syndrome are mycobacteria, varicella zoster, herpesviruses, and
cytomegalovirus (CMV). No single treatment option exists and depends on the underlying
infectious agent and its clinical presentation. Prospective cohort studies addressing the optimal
screening and treatment of opportunistic infections in patients eligible for ART are currently being
conducted. These studies will provide evidence for the development of treatment guidelines in
order to reduce the burden of IRIS. We review the available literature on the pathogenesis and
epidemiology of IRIS, and present treatment options for the more common infectious
manifestations of this diverse syndrome and for manifestations associated with a high morbidity.
Introduction
Since its introduction, ART has led to significant declines
in AIDS-associated morbidity and mortality [1]. These
benefits are, in part, a result of partial recovery of the
immune system, manifested by increases in CD4+ T-lym-
phocyte counts and decreases in plasma HIV-1 viral loads
[2]. After initiation of ART, opportunistic infections (OI)
and other HIV-related events still occur secondary to a
delayed recovery of adequate immunity [3].
Some patients initiating ART experience unique symp-
toms during immune system recovery. In these patients,
clinical deterioration occurs despite increased CD4+ T-
lymphocyte counts and decreased plasma HIV-1 viral
loads [4]. This clinical deterioration is a result of an
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system to both intact subclinical pathogens and residual
antigens [5-9]. Resulting clinical manifestations of this
syndrome are diverse and depend on the infectious or
noninfectious agent involved. These manifestations
include mycobacterial-induced lymphadenitis [5], para-
doxical tuberculosis reactions [6,7,10,11], worsening of
progressive multifocal leukoencephalopathy (PML) [12],
recurrence of cryptococcosis and Pneumocystis jirovecii
pneumonia (PCP) [8,13-16], Cytomegalovirus (CMV)
retinitis [17], shingles [18], and viral hepatitis [19], as well
as noninfectious phenomena [20].
Because clinical deterioration occurs during immune
recovery, this phenomenon has been described as
immune restoration disease (IRD), immune reconstitu-
tion syndrome (IRS), and paradoxical reactions. Given the
role of the host inflammatory response in this syndrome,
the term immune reconstitution inflammatory syndrome
(IRIS) has been proposed [21] and has become the most
widely used and accepted term to describe the clinical
entity. Possible infectious and noninfectious etiologies of
IRIS are summarized in Table 1.
To date, no prospective therapeutic trials concerning the
management of IRIS have been conducted. All evidence
regarding the management of IRIS in the literature relates
to case reports and small case series reporting on manage-
ment practice. This does not provide reliable evidence
regarding either the safety or efficacy of these approaches,
but merely guidance regarding the practice of others in
managing this difficult condition. In severe cases where
the discontinuation of ART is a possibility, the potential
disadvantages of therapy cessation, such as the develop-
ment of viral resistance or AIDS progression, should be
considered.
Pathogenesis of IRIS
Despite numerous descriptions of the manifestations of
IRIS, its pathogenesis remains largely speculative. Current
theories concerning the pathogenesis of the syndrome
involve a combination of underlying antigenic burden,
the degree of immune restoration following HAART, and
host genetic susceptibility. These pathogenic mechanisms
may interact and likely depend on the underlying burden
of infectious or noninfectious agent.
Whether elicited by an infectious or noninfectious agent,
the presence of an antigenic stimulus for development of
the syndrome appears necessary. This antigenic stimulus
can be intact, "clinically silent" organisms or dead or
dying organisms and their residual antigens. IRIS that
occurs as a result of "unmasking" of clinically silent infec-
tion is characterized by atypical exuberant inflammation
and/or an accelerated clinical presentation suggesting a
restoration of antigen-specific immunity. These character-
istics differentiate IRIS from incident opportunistic infec-
tions that occur on ART as a result of delayed adequate
immunity.
Examples of IRIS in response to intact organisms include,
but are not limited to, the unmasking of latent cryptococ-
cal infection [22] and infection with Mycobacterium avium
complex (MAC) [4,5,23,24]. The most frequently
reported IRIS symptoms in response to previously treated
or partially treated infections include reports of clinical
worsening and recurrence of clinical manifestations of
Mycobacterium tuberculosis (TB) and cryptococcal meningi-
tis following initiation of ART [6,7,10,13,16,25-28]. In
noninfectious causes of IRIS, autoimmunity to innate
antigens plays a likely role in the syndrome. Examples
include exacerbation of rheumatoid arthritis and other
autoimmune diseases [29]. Given the role of this anti-
genic stimulus, the frequency and manifestations of IRIS
in a given population may be determined by the preva-
lence of opportunistic and non-opportunistic infections
to initiation of ART.
The mechanism receiving the most attention involves the
theory that the syndrome is precipitated by the degree of
immune restoration following ART. In assessing this the-
ory, investigators have examined the association between
CD4 cell counts and viral loads and the risk of IRIS. Some
studies suggest differences in the baseline CD4 profiles or
quantitative viral load at ART initiation or their rate of
change during HAART between IRIS and non-IRIS
patients [4,30-34], while other studies demonstrate only
trends or no significant difference between IRIS and non-
IRIS patients [7,35]. These immunological differences
between groups have been difficult to verify due to small
numbers of IRIS cases and lack of control groups. An alter-
native immunological mechanism may involve qualita-
tive changes in lymphocyte function or lymphocyte
phenotypic expression. For instance, following ART an
increase in memory CD4 cell types is observed [36] possi-
bly as a result of redistribution from peripheral lymphoid
tissue [37]. This CD4 phenotype is primed to recognize
previous antigenic stimuli, and thus may be responsible
for manifestations of IRIS seen soon after ART initiation.
After this redistribution, naïve T cells increase and are
thought to be responsible for the later quantitative
increase in CD4 cell counts [38]. These data suggest IRIS
may be due to a combination of both quantitative resto-
ration of immunity as well as qualitative function and
phenotypic expression observed soon after the initiation
of ART.
The third purported pathogenic mechanism for IRIS
involves host genetic susceptibility to an exuberant
immune response to the infectious or noninfectious anti-Page 2 of 10
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dence is limited, carriage of specific HLA alleles suggest
associations with the development of IRIS and specific
pathogens [39]. Increased levels of interleukin-6 (IL-6) in
IRIS patients may explain the exuberant Th1 response to
mycobacterial antigens in subjects with clinical IRIS
[9,40]. Such genetic predispositions may partially explain
why manifestations of IRIS differ in patients with similar
antigenic burden and immunological responses to ART.
Epidemiology of IRIS
Despite numerous descriptions of the infectious and non-
infectious causes of IRIS, the overall incidence of the syn-
drome itself remains largely unknown. Studies to date are
often retrospective and focus on specific manifestations of
IRIS, such as tuberculosis-associated IRIS (TB-IRIS). In a
large retrospective analysis examining all forms of IRIS,
33/132 (25%) of patients exhibited one or more disease
episodes after initiation of ART [4]. Other cohort analyses
examining all manifestations of IRIS estimate that 17–
23% of patients initiating ART will develop the syndrome
[32-34]. Another large retrospective study reported 32%
of patients with M. tuberculosis, M. avium complex, or
Cryptococcus neoformans coinfection developed IRIS after
initiating ART.
Risk factors identified for the development of IRIS in one
cohort included male sex, a shorter interval between initi-
ating treatment for OI and starting ART, a rapid fall in
HIV-1 RNA after ART, and being ART-naïve at the time of
OI diagnosis [31]. Other significant predictors have also
included younger age, a lower baseline CD4 cell percent-
age, a lower CD4 cell count at ART initiation, and a lower
CD4 to CD8 cell ratio at baseline [4,32]. It should be
noted cohorts differ substantially in study populations
and the type of IRIS (i.e. TB-IRIS only) examined, making
conclusions regarding risk factors for IRIS difficult. Clini-
cal factors associated with the development of IRIS are
presented in Table 2.
Case reports describing different clinical manifestations of
IRIS continue to appear, expanding the clinical spectrum
of the syndrome. Because the definition of IRIS is one of
clinical suspicion and disease-specific criteria have yet to
be developed, determining the true incidence will be dif-
ficult. Taken together, these studies suggest IRIS may affect
a substantial proportion of HIV patients initiating ART.
Future epidemiologic and genetic studies conducted
within diverse cohorts will be important in determining
the importance of host susceptibility and underlying
opportunistic infections on the risk of developing IRIS.
Disease-specific manifestations of IRIS
In order to aid clinicians in the management of IRIS, we
review the epidemiology, clinical features, and treatment
options for the common infectious manifestations of
IRIS. Additionally, manifestations associated with signifi-
cant morbidity and mortality, such as CMV-associated
immune recovery vitritis (IRV) or immune recovery uvei-
tis (IRU), are also reviewed. Treatment options and their
evidence are presented. Until disease specific guidelines
are developed for IRIS, therapy should be based on exist-
Table 1: Infectious and noninfectious causes of IRIS in HIV-infected patients
Infectious Etiologies Noninfectious etiologies
Mycobacteria Rheumatologic/Autoimmune
Mycobacterium tuberculosis [4, 6, 7, 10, 11, 26, 30-32, 41, 43, 45] Rheumatoid arthritis [29] Systemic lupus erythematosus (SLE) [91]
Graves disease [92], Autoimmune thyroid disease [93]
Mycobacterium avium complex [4, 5, 23, 31, 94-96] Sarcoidosis & granulomatous reactions [20, 97]
Other mycobacteria [4, 56, 57, 98, 99] Tattoo ink [100]
Cytomegalovirus [4, 33, 61, 63] AIDS-related lymphoma [101]
Herpes viruses Guillain-Barre' syndrome (GBS) [102]
Herpes zoster virus [4, 32, 33, 71, 103, 104] Interstitial lymphoid pneumonitis [105]
Herpes simplex virus [4, 32, 33]
Herpes virus-associated Kaposi's sarcoma [4, 32, 106]
Cryptococcus neoformans [13, 16, 22, 28, 31, 83, 84, 86, 88]
Pneumocystis jirovecii pneumonia (PCP) [8, 14, 32]
Histoplasmosis capsulatum [107]
Toxoplasmosis [33]
Hepatitis B virus [32, 33]
Hepatitis C virus [4, 32, 33, 108]
Progressive multifocal leukoencephalitis [12, 33, 109]
Parvovirus B19 [110]
Strongyloides stercoralis infection [111] & other parasitic infections [112]
Molluscum contagiosum & genital warts [32]
Sinusitis [113]
Folliculitis [114, 115]Page 3 of 10
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of presentation.
Mycobacterium tuberculosis IRIS
Epidemiology
Mycobacterium tuberculosis (TB) is among the most fre-
quently reported pathogen associated with IRIS. Narita et
al performed the first prospective study to evaluate the
incidence of paradoxical responses in patients on TB ther-
apy and subsequently initiated on ART. Of 33 HIV/TB
coinfected patients undergoing dual therapy, 12 (36%)
developed paradoxical symptoms [7]. The frequency of
symptoms in this group were greater than those observed
in HIV-infected controls receiving TB therapy alone, sup-
porting the role of an exaggerated immune system
response in the pathogenesis of the syndrome. Retrospec-
tive studies corroborate the finding that a significant pro-
portion of HIV/TB coinfected patients undergoing HAART
have symptoms consistent with IRIS, with estimates rang-
ing from 7–45% [10,26,30,35,41-43].
The association between a shorter delay between TB treat-
ment initiation and ART initiation is an area of debate.
While some investigators have found no difference in
time from TB therapy to initiation of ART between IRIS
and non-IRIS subjects [30], others have reported a signifi-
cant differences between groups [31,35]. In general, IRIS
occurred in subjects initiated on ART within two months
of TB therapy initiation [35]. Based on these and other
data, a decision analysis on ART initiation timing in TB
patients found the highest rates of IRIS occurred in
patients initiated on ART within two months of TB ther-
apy initiation [44]. However, withholding or deferring
ART until two to six months of TB therapy was associated
with higher mortality in scenarios where IRIS-related mor-
tality was less than 4.6%. Future reports from large, pro-
spective observational cohorts may aid in resolving this
difficult issue.
Although consisting primarily of case reports [45,46], TB-
IRIS affecting the central nervous system (CNS) poses a
unique problem. As the availability of ART increases in
endemic countries, the incidence of CNS TB-IRIS may
increase. Thus, clinicians should be vigilant in its diagno-
sis.
Clinical features
The commonest clinical manifestations of TB-IRIS are
fever, lymphadenopathy and worsening respiratory symp-
toms [47]. Pulmonary disorders, such as new pulmonary
infiltrates, mediastinal lymphadenopathy, and pleural
effusions are also common [7]. Extrapulmonary presenta-
tions are also possible, including disseminated tuberculo-
sis with associated acute renal failure [6], systemic
inflammatory responses (SIRS) [48], and intracranial
tuberculomas [45]. Pulmonary TB-IRIS can be diagnosed
by transient worsening of chest radiographs, especially if
old radiographs are available for comparison. Other
symptoms are nonspecific, and include persistent fever,
weight loss, and worsening respiratory symptoms.
Abdominal TB-IRIS can present with nonspecific abdom-
inal pain and obstructive jaundice.
In most studies, TB-IRIS occurs within two months of ART
initiation [6,7,10,11,25,35,45,48]. Among 43 cases of
MTB-associated IRIS, the median onset of IRIS was 12–15
days (range 2–114 days), with only four of these cases
occurring more than four weeks after the initiation of
antiretroviral therapy [7,10,25,26,30]. These studies sug-
gest the onset of mycobacterial-associated IRIS is relatively
soon after initiation of ART, and clinicians should main-
tain a high level of vigilance during this period.
Paradoxical CNS TB reactions are well described in HIV-
negative patients, and include expanding intracranial
tuberculomas, tuberculous meningitis, and spinal cord
lesions [49-51]. TB-associated CNS IRIS has also been
reported in HIV-positive patients [45,46,52]. Compared
to non-CNS TB-IRIS, symptoms tend to occur later, usu-
ally 5–10 months after ART initiation [45,50,52]. Crump
et al [45] described an HIV-seropositive patient in who
developed cervical lymphadenopathy after five weeks of
Table 2: Clinical factors associated with the development of IRIS†
Risk factor Reference
Male sex [31]
Younger age [32]
Lower CD4 cell count at ART initiation [4]
Higher HIV RNA at ART initiation [4]
Lower CD4 cell percentage at ART initiation [32]
Lower CD4:CD8 ratio at ART initiation [32]
More rapid initial fall in HIV RNA on ART [31]
Antiretroviral naïve at time of OI diagnosis [31]
Shorter interval between OI therapy initiation and ART initiation [31]
†Derived from cohorts where IRIS due to multiple pathogens were reported (i.e. cohorts which examined only TB-IRIS were excluded)Page 4 of 10
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expanding intracranial tuberculoma appeared after initia-
tion of antituberculous therapy. The significant morbidity
in this case illustrates the importance of maintaining a
high clinical suspicion for the disease, particularly in
endemic areas.
Treatment
Treatment for mycobacterial-associated IRIS depends on
the presentation and disease severity. Most patients
present with non-life threatening presentations which
respond to the institution of appropriate antituberculous
therapy. However a range of life threatening presenta-
tions, such as acute renal failure [6] and acute respiratory
distress syndrome (ARDS) [11], are described and have
significant morbidity and mortality. Morbidity and mor-
tality might also be greater in resource-limited settings
where limited management options exist. Since the patho-
genesis of the syndrome is an inflammatory one, systemic
corticosteroids or nonsteroidal anti-inflammatory drugs
(NSAIDS) may alleviate symptoms. In studies where ther-
apy for IRIS was mentioned, the use of corticosteroids was
variable [7,24,25,31,41,43] and anecdotally effective.
Therapies ranged from intravenous methylprednisolone
40 mg every 12 hours to prednisone 20–70 mg/day for 5–
12 weeks. These practices reflect the lack of evidence from
controlled trials for the use of anti-inflammatory agents in
IRIS. A randomized, placebo controlled trial examining
doses of prednisone 1.5 mg/kg/day for two weeks fol-
lowed by 0.75 mg/kg/day for two weeks in mild to mod-
erate TB-IRIS is currently underway in South Africa. Until
data become available, it is reasonable to administer cor-
ticosteroids for severe cases of IRIS such as tracheal com-
pression due to lymphadenopathy, refractory or
debilitating lymphadenitis, or severe respiratory symp-
toms, such as stridor and ARDS. Interruption of ART is
rarely necessary but could be considered in life-threaten-
ing situations.
In HIV-negative patients, adjuvant corticosteroid use in
tuberculous meningitis provides evidence of improved
survival and decreased neurologic sequelae over standard
therapy alone [53,54]. Once other infectious etiologies,
have been excluded, standard antituberculous therapy
should be initiated or continued as the clinical situation
dictates, and a course of corticosteroid therapy should be
considered for CNS TB-IRIS. Continuation of ART is desir-
able, although its discontinuation may be necessary in
unresponsive cases or in those presenting with advanced
neurological symptoms.
Atypical mycobacterial IRIS
Epidemiology
In addition to TB, atypical mycobacteria are also fre-
quently reported as causative pathogens in IRIS. Early
observations involving atypical presentations of Mycobac-
terium avium-intracellulare (MAC) were first noted with
zidovudine therapy [55]. Reports of atypical presentations
of both Mycobacterium tuberculosis (MTB) and MAC
increased in frequency with the introduction of protease
inhibitors and ART. In larger cohorts, MAC remains the
most frequently reported atypical mycobacterium
[4,5,24]. Other atypical mycobacteria rarely associated
with IRIS are referenced in Table 1.
Clinical features
In general, MAC-associated IRIS typically presents with
lymphadenitis, with or without abscess formation and
suppuration [5]. Other less common presentations
include respiratory failure secondary to acute respiratory
distress syndrome (ARDS) [56], leprosy [57], pyomyositis
with cutaneous abscesses [23], intra-abdominal disease
[58], and involvement of joints, skin, soft tissues, and
spine [58,59].
Several studies have characterized the time of onset of
Mycobacterium-associated IRIS. In one study of MAC lym-
phadenitis, the onset of a febrile illness was the first sign
of IRIS and occurred between 6 and 20 days after initia-
tion of antiretroviral therapy [5]. In another study, the
median time interval from the start of antiretroviral ther-
apy to the development of mycobacterial lymphadenitis
was 17 days (range 7–85 days) [24].
Treatment
As with TB-IRIS, evidence for treatment of IRIS due to
atypical mycobacteria are scarce. Occasionally, surgical
excision of profoundly enlarged nodes or debridement of
necrotic areas is anecdotally reported [23,59]. However,
healing is often poor leaving large, persistent sinuses. Nee-
dle aspiration is another option for enlarged, fluctuant
and symptomatic nodes. Otherwise, treatment is similar
to TB-IRIS (see Mycobacterium tuberculosis IRIS – Treat-
ment).
Cytomegalovirus infection
Epidemiology
In the pre-ART era, CMV retinitis, a vision-threatening dis-
ease, carried a high annual incidence and was one of the
most significant AIDS-associated morbidities [60]. After
the introduction of HAART, Jacobson et al described five
patients diagnosed with CMV retinitis 4–7 weeks after
ART initiation. They speculated that an HAART-induced
inflammatory response may be responsible for unmask-
ing a subclinical infection [17]. In addition to classical
CMV retinitis, ART led to new clinical manifestations of
the infection, termed immune recovery vitritis (IRV) or
immune recovery uveitis (IRU), in patients previously
diagnosed with inactive AIDS-related CMV retinitis [61].
Distinct from the minimal intraocular inflammation ofPage 5 of 10
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cant posterior segment ocular inflammation thought to be
due to the presence of residual CMV antigens or proteins
which serve as the antigenic stimulus for the syndrome
[62]. Clinical manifestations include vision impairment
and floaters.
In a retrospective cohort, CMV-related IRIS was common
(6/33 of IRIS cases, or 18%) [4]. In prospective cohorts,
symptomatic vitritis occurred in 63% (incidence rate 83
per 100 p-yr) of ART responders who carried a previous
diagnosis of CMV retinitis but had inactive disease at the
onset of antiretroviral therapy. The median time from ART
initiation to IRV was (43 weeks)[63]. Another large pro-
spective surveillance study [64] identified 374 patients
with a history of CMV retinitis involving 539 eyes. Thirty-
one of 176 ART responders (17.6%) were diagnosed with
IRU. Male gender, use of ART, higher CD4 cell counts, and
involvement of the posterior retinal pole as factors associ-
ated with a reduced risk of developing IRU, whereas prior
use of intravitreous injections of cidofovir, large retinal
lesions, and adequate immune recovery on ART were
associated with increased risk.
Clinical features & treatment
The diagnosis of ocular manifestations of IRIS requires a
high level of suspicion. In addition to signs of retinitis,
inflammatory symptoms include vitritis, papillitis, and
macular edema, resulting in symptoms of loss of visual
acuity and floaters in affected eyes. Treatment of IRIS asso-
ciated CMV retinitis and IRV may involve anti-CMV ther-
apy with gancyclovir or valgancyclovir[17,65]. However,
the occurrence of IRU in patients receiving anti-CMV ther-
apy draws its use into question [64,66,67]. The use of sys-
temic corticosteroids has been successful, and IRV may
require periocular corticosteroid injections [61,68-70].
Due to its significant morbidity and varying temporal
presentations, clinicians should maintain a high level of
vigilance for ocular manifestations of CMV-associated
IRIS.
Varicella zoster virus infection
Epidemiology
With the introduction of protease inhibitors, increasing
rates of herpes zoster were noted in HIV-infected patients.
Two studies comparing ART and non-ART patients
reported increased incident cases of zoster and rates esti-
mated at 6.2–9.0 cases per 100 person-years, three to five
times higher than rates observed in the pre-HAART era
[18,71]. While another study [72] reported no difference
in overall incidence between HAART eras (3.2 cases per
100 person-years), the use of HAART was associated with
increased odds of developing an incident zoster outbreak
(OR = 2.19, 95% confidence interval: 1.49 to 3.20). These
studies suggest that ART may play a role in increasing the
risk of zoster, which is reflected in large observational IRIS
cohorts, where dermatomal varicella zoster comprises 9–
40% of IRIS cases [4,32,33]. Mean onset of disease from
ART initiation was 5 weeks (range 1–17 weeks) [71], and
no cases occurred before 4 weeks of therapy [18]. Both
studies identified significant increases in CD8 T cells as a
risk factor for developing dermatomal zoster.
Clinical features & treatment
Although complications such as encephalitis, myelitis,
cranial and peripheral nerve palsies, and acute retinal
necrosis can occur in immunocompromised HIV patients,
the vast majority of patients exhibit typical or atypical der-
matomal involvement without dissemination or systemic
symptoms [18,71,73].
A randomized, controlled trial demonstrated oral acyclo-
vir to be effective for dermatomal zoster in HIV-infected
patients, facilitating healing and shortening the time of
zoster-associated pain [74]. Its use in cases of varicella
zoster IRIS appears to be of clinical benefit [18]. The ben-
efit of corticosteroids in combination with acyclovir in
acute varicella zoster has been demonstrated in two large
randomized, controlled trials. The combination of corti-
costeroids and acyclovir decreased healing times,
improved acute pain, and quality of life, but did not affect
the incidence or duration of postherpetic neuralgia
[75,76]. The incidence of postherpetic neuralgia in immu-
nocompetent individuals does not differ significantly
from HIV-infected patients, but increases with increasing
patient age [77]. Successful symptomatic management
involving opioids, tricyclic antidepressants, gabapentin,
and topical lidocaine patches individually or in combina-
tion has been shown to be beneficial [78-82] and should
be attempted in HIV patients with postherpetic neuralgia
as a complication of herpes zoster IRIS.
Cryptococcus neoformans infection
Epidemiology
Accurate incidence of C. neoformans-associated IRIS is
unknown. It is infrequently reported in overall IRIS
cohorts, and many cases appear as single case reports. The
majority of cryptococcal IRIS cases represent reactivation
of previously treated cases [13,16,21,22,83-86], suggest-
ing either an immunological reaction to incompletely
treated disease or an inflammatory reaction to residual
antigens. Although reports of cryptococcal lymphadenitis
and mediastinitis have been reported [87,88], most cryp-
tococcal IRIS cases present as meningitis. Of 41 well doc-
umented cases of cryptococcal IRIS meningitis, 33 (80%)
result as a reactivation of C. neoformans meningitis
[13,16,21,22,83-86,89], illustrating the importance of
maintaining a high clinical suspicion for patients at risk
for cryptococcal IRIS, even in those previously treated.Page 6 of 10
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C. neoformans-induced IRIS meningitis symptoms range in
onset from seven days to ten months after initiation of
ART, with 20 (49%) occurring within four weeks of ther-
apy [13,16,21,22,83-86,89]. In one study [85], patients
with C. neoformans-related IRIS meningitis were compared
to typical AIDS-related C. neoformans meningitis. Patients
with C. neoformans-related IRIS meningitis exhibited no
difference in clinical presentation. However, C. neoform-
ans-related IRIS patients exhibited had higher baseline
plasma HIV RNA levels and higher CSF cryptococcal anti-
gen titers, opening pressures, WBC counts, and glucose
levels. Additionally, IRIS patients were more likely to have
ART initiated within 30 days of previously diagnosed C.
neoformans meningitis. Most documented cases of C. neo-
formans-induced IRIS meningitis have occurred in patients
with CD4 counts <100 cells/mm3 [13,21,83-85,87].
Treatment
A recent study [90] evaluated antifungal combination
therapies in the treatment of C. neoformans meningitis in
HIV patients. Although significant log reductions in col-
ony forming units were observed with all combinations,
substantial numbers of patients remained culture positive
2 weeks after therapy. It may be important to delay ART
until CSF sterility can be achieved with effective antifungal
combinations such as amphotericin B and flucytosine.
However, the exact timing of ART and whether attaining
CSF culture sterility is important in avoiding IRIS is
unknown. This is illustrated by cases of reactivation cryp-
tococcal meningitis described in four patients who had
received at least four weeks of antifungal therapy prior to
ART [13,22,83]. It is reasonable to administer systemic
corticosteroids to alleviate unresponsive inflammatory
effects, as anecdotal benefits have been observed in these
patients [21,84]. Furthermore, serial lumbar punctures
may be required to manage persistent CSF pressure eleva-
tions in these patients [85,86]. Although continuation of
ART has been performed safely [13,84], interruption of
antiviral therapy may be necessary in severe or unrespon-
sive cases.
Other etiologies
Other less common infectious etiologies, as well as non-
infectious etiologies, are listed in Table 1. Because these
other infectious and non-infectious etiologies are rare, no
recommendations exist for their management.
Conclusion
While exact estimates of incidence are not yet available,
IRIS in patients initiating ART has been firmly established
as a significant problem in both high and low income
countries. Because of wide variation in clinical presenta-
tion and the still increasing spectrum of symptoms and
etiologies reported, diagnosis remains problematic. Fur-
thermore, no test is currently available to establish an IRIS
diagnosis. Standardized disease-specific clinical criteria
for common infectious manifestations of the disease
should be developed to: 1) identify risk factors for devel-
oping the syndrome and 2) optimize the prevention,
management of opportunistic infections. Results of trials
addressing the optimal timing and duration of treatment
of opportunistic infections will assist in developing guide-
lines for the prevention and management of IRIS. Treat-
ment of IRIS will remain a clinical challenge due to the
variety of clinical presentations and the presence of multi-
ple pathogens capable of causing the syndrome. Until a
greater understanding of the syndrome is achieved in dif-
ferent regions of the world, clinicians need to remain vig-
ilant when initiating ART and individualize therapy
according to known treatment options for the specific
infectious agent.
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